Key points are not available for this paper at this time.
Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jedd D. Wolchok
Vanna Chiarion‐Sileni
Piotr Rutkowski
New England Journal of Medicine
Cornell University
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Wolchok et al. (Sun,) studied this question.
www.synapsesocial.com/papers/68e587eeb6db643587523f6f — DOI: https://doi.org/10.1056/nejmoa2407417
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: